Trial Profile
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- 13 Nov 2018 Status changed from active, no longer recruiting to completed.
- 15 Jan 2015 Planned primary completion date changed to 1 Oct 2015, according to ClinicalTrials.gov record.
- 15 Jan 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.